This study identified ten potential targets for the treatment of T2DM combined with CRC using GQD, among which GSR and MAPK9 were aberrantly expressed in both T2DM and CRC and significantly associated with CRC prognosis. The gene discussed is MAPK9; the disease is type 2 diabetes mellitus.